Thus NRG-1 has a complex role in inherited demyelinating neuropathies, but these studies demonstrate that there may be a therapeutic window for exogenous NRG-1 early on in the disease course for genetic neuropathies such as CMT1A. This evidence concerns the gene NRG1 and Charcot-Marie-Tooth disease type 1A.